Blood Manganese Correlates with Brain Magnetic Resonance Imaging Changes in Patients with Liver Disease

Robert A. Hauser, Theresa A. Zesiewicz, Carlos Martinez, Alexander S. Rosemurgy and C.W. Olanow

ABSTRACT: Background: Chronic liver failure is associated with high signal abnormalities in the basal ganglia on T1-weighted magnetic resonance imaging of the brain. These abnormalities are strikingly similar to those seen following manganese intoxication. As dietary manganese is normally cleared by the liver, we hypothesize that hepatic dysfunction could lead to manganese overload and account for the MRI abnormalities seen in patients with chronic liver disease. Methods: We measured blood manganese concentrations in eleven patients with biopsy-proven hepatic cirrhosis and eleven healthy age and sex-matched controls. We also performed semi-quantitative measures of T1 signal abnormalities on MRI in the patients with chronic liver disease. Results: Patients with cirrhosis had significantly higher blood manganese concentrations (20.6 ± 10.2 mcg/L) than controls (7.2 ± 2.7, p = .0013). In addition, semi-quantitative scores of T1-weighted signal hyperintensity on MRI correlated with blood manganese concentration in patients with cirrhosis (r = .65, p = .029). Conclusions: These findings demonstrate that chronic liver disease is associated with manganese overload and suggest that manganese is responsible for the T1-weighted signal hyperintensity seen on MRI of patients with liver disease. As manganese intoxication is known to cause parkinsonism and an encephalopathy similar to those which occur with chronic liver disease, it is possible that manganese toxicity contributes to the development of these symptoms in liver damaged patients and that therapies which prevent or reduce manganese overload may have clinical benefit.

RESUME: Le taux de manganese sanguin est en correlation avec les changements observees a l'imagerie par resonance magnetique chez les patients avec atteinte hepatique. Introduction: L'insuffisance hepatique chronique est associee a des anomalies du signal dans le noyau lenticulaire, le noyau caudex, l'avant-mur et le noyau amygdalien a l'imagerie par resonance magnetique avec ponderation T1 du cerveau. Ces anomalies sont efronnant semblables a celles observees dans l'intoxication au manganese. Comme le manganese de la diete est normalement eliminee par le foie, nous avons emis l'hypothese qu'une dysfonction hepatique pourrait engendrer une surcharge en manganese et etre responsable des anomalies observees a lIRM chez les patients atteints de maladie hepatique chronique. Methodes: Nous avons mesure la concentration de manganese sanguin chez onze patients avec cirrhose hepatique prouvee par biopsie et onze controles sains, apparus pour l'age et le sexe. Nous avons egalement realise des mesures semi-quantitatives des anomalies de signal T1 a lIRM chez les patients atteints de maladie hepatique chronique. Resultats: Les patients atteints de cirrhose avaient des concentrations sanguines de manganese significativement plus elevees (20.6 ± 10.2 mcg/L) que les controles (7.2 ± 2.7, p=.0013). De plus, les scores semi-quantitatives de l'hyperintensite du signal pondere T1 a lIRM etaient correles avec les concentrations sanguines de manganese chez les patients atteints de cirrhose (r=65, p=.029). Conclusions: Ces observations demontrent que la maladie hepatique chronique est associee a une surcharge en manganese et suggèrent que le manganese est responsable de l'hyperintensite du signal pondere T1 observe a lIRM des patients atteints de maladie hepatique. Il est connu que l'intoxication au manganese cause un parkinsonisme et une encéphalopathie semblables a ce qui est observe dans la maladie hepatique chronique. Il est donc possible que la toxicite du manganese contribue au developpement de ces symptomes chez les patients avec atteinte hepatique et que les traitements qui previennent ou diminuent la surcharge en manganese puissent avoir un benefice clinique chez ces patients.


Chronic liver failure is associated with abnormal increased signal intensity in the globus pallidus (GP), putamen, substantia nigra (SN), and anterior pituitary on T1-weighted magnetic resonance imaging of the brain.1-3 The cause of these signal abnormalities is presently unknown. T1-weighted signal hyperintensity can be associated with lipids,4 methemoglobin,5 melanoma,6 calcification,7 neurofibromatosis8 and manganese.9,10 However, only manganese (Mn) is known to cause an abnormal increase in T1-weighted signal in the same distribution as observed in patients with chronic liver disease. We have hypothesized that patients with chronic liver disease may suffer Mn overload due to decreased hepatic elimination of normal dietary Mn.11 To test this hypothesis, we compared blood Mn concentrations in patients with biopsy-proven cirrhosis to those of healthy controls and evaluated the correlation between blood Mn concentration and the extent of T1-weighted signal hyperintensity on MRI.

From the Departments of Neurology (R.A.H., T.A.Z.), Radiology (C.M.), and Surgery (A.S.R.), University of South Florida, Tampa, Florida and the Department of Neurology, Mount Sinai School of Medicine (C.W.O.), New York, New York.

Reprint requests to: C. Warren Olanow, M.D., F.R.C.P.(C), Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1137, New York, New York 10029 USA.
METHODS

Eleven patients with biopsy-proven cirrhosis underwent MRI of the brain and determination of blood Mn concentration. Blood Mn concentrations were also obtained in 11 age and sex-matched healthy controls. Consecutive patients with liver-biopsy confirmed cirrhosis were selected for the study from an ambulatory care hepatology clinic. Controls consisted of employees and family members of patients with no history of liver disease. All participants signed an informed consent. Blood Mn assays were performed by Smith Kline Beecham Clinical Laboratories using graphite furnace atomic absorption spectroscopy and were verified by repeat analysis. All blood samples were collected in an identical fashion and assayed by blinded technicians. A t-test was used to compare blood Mn concentrations between patients with cirrhosis and normal controls.

MRI studies of the brain were performed on a General Electric Signa 1.5 Tesla system. MR images were obtained in T1-weighted sagittal (TR/TE = 350/19 ms), axial (TR/TE = 500/19 ms), and coronal (TR/TE = 500/19 ms) planes; spin-echo axial (TR/TE = 3200/18 ms) and coronal (TR/TE = 2400/30 ms) planes; and, T2-weighted axial (TR/TE = 3200/126 ms) and coronal (2400/80 ms) planes. MR images were evaluated by a blinded neuroradiologist (CM) using a semi-quantitative scale. Signal intensity was graded as normal (0), mildly abnormal (1+), or markedly abnormal (2+) in each of the GP, putamen, caudate nucleus, thalamus, SN, tectum, central pons, and anterior pituitary. Additional MRI abnormalities were recorded when present.

RESULTS

Eleven patients with biopsy-proven hepatic cirrhosis participated in the study (Table 1). Eight (73%) were male. The mean age (± SD) was 56.9 ± 10.9 years, and the average disease duration was 9.1 ± 10.5 years. The presumed cause of cirrhosis was alcohol abuse in 5 cases, infectious hepatitis in 3, and unknown in 3. None of the patients had Wilson’s disease, Systemic Lupus Erythematosi, a history of prior parenteral nutrition, or were taking portal shunt.

Patients with cirrhosis had a mean blood Mn concentration of 20.6 ± 10.2 mcg/L. This compared with control individuals who had a mean blood Mn concentration of 7.2 ± 2.7 mcg/L. These values were significantly different using a t-test for samples with unequal variance (p = .0013).

Abnormal T1-weighted signal hyperintensity was present on MRI in 10 of 11 (91%) patients with chronic liver disease (Figure 1). Total T1 scores for individual patients are shown in Table 1 and regional distribution is illustrated in Table 2. Signal abnormality was most commonly observed in the SN and GP and was most pronounced in the GP. Abnormal T1-weighted signal hyperintensity in the putamen, tectum and anterior pituitary was also noted in some patients. Signal abnormalities were not observed in the caudate, thalamus or pons in any patient. No signal changes were detected in any of these regions on T2-weighted or spin echo scans. Atrophy was present in 6 cases (55%). In 5, the atrophy was generalized. In 1, atrophy was confined to the cerebellum. No other radiologic abnormalities were detected.

There was a significant correlation between total T1 score and blood Mn concentration as shown in Figure 2 (r = 0.65; p = .029). The T1 scores and Mn levels were normally distributed on the Wilks-Shapiro test, justifying assumptions for employing the Pearson correlation coefficient. Similar results were obtained with non-parametric analyses.

DISCUSSION

We demonstrate significantly higher blood Mn concentrations in patients with biopsy-proven hepatic cirrhosis than healthy age and sex-matched controls. These findings are consistent with the findings of earlier investigators. We also establish that blood Mn concentrations correlate with T1 signal abnormality on MRI in patients with chronic hepatic dysfunction. These findings support the notion that Mn accumulation accounts for the signal abnormalities seen on MRI in this patient population and raise the possibility that Mn may contribute to neurologic dysfunction in patients with chronic liver disease.

Mn is a trace metal which is essential for normal life, but can cause neurotoxicity at high concentrations. Within the brain, Mn accumulates in the GP and the pars reticularis portion of the SN where it is primarily localized within mitochondria and

Table 1: Baseline characteristics, MRI scores and blood Mn levels of 11 patients with biopsy-proven cirrhosis.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>Etiology</th>
<th>Duration (Yrs)</th>
<th>Shunt</th>
<th>Blood Mn (mcg/l)</th>
<th>Total T1 Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>40</td>
<td>M</td>
<td>Hepatitis C</td>
<td>10</td>
<td>-</td>
<td>45.0</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>M</td>
<td>ETOH</td>
<td>10</td>
<td>-</td>
<td>20.1</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>45</td>
<td>M</td>
<td>Hepatitis C</td>
<td>2</td>
<td>+</td>
<td>12.2</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>53</td>
<td>F</td>
<td>UNK</td>
<td>5</td>
<td>+</td>
<td>28.2</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>38</td>
<td>M</td>
<td>ETOH</td>
<td>5</td>
<td>+</td>
<td>26.2</td>
<td>4</td>
</tr>
<tr>
<td>6</td>
<td>65</td>
<td>M</td>
<td>UNK</td>
<td>2</td>
<td>-</td>
<td>20.4</td>
<td>4</td>
</tr>
<tr>
<td>7</td>
<td>69</td>
<td>F</td>
<td>UNK</td>
<td>2</td>
<td>+</td>
<td>18.9</td>
<td>4</td>
</tr>
<tr>
<td>8</td>
<td>56</td>
<td>M</td>
<td>ETOH</td>
<td>6</td>
<td>+</td>
<td>18.8</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>67</td>
<td>F</td>
<td>Hepatitis C</td>
<td>39</td>
<td>+</td>
<td>11.3</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>61</td>
<td>M</td>
<td>ETOH</td>
<td>7</td>
<td>+</td>
<td>6.6</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>65</td>
<td>M</td>
<td>ETOH</td>
<td>13</td>
<td>+</td>
<td>19.5</td>
<td>0</td>
</tr>
</tbody>
</table>

M = male, F = female, ETOH = alcohol abuse, UNK = unknown.
Figure 1: T1-weighted sagittal and axial MRI of a patient with hepatic cirrhosis demonstrating signal hyperintensity in the globi pallidi.

Table 2: Distribution, frequency and severity of abnormal signal hyperintensity in patients with chronic liver disease.

<table>
<thead>
<tr>
<th></th>
<th>GP</th>
<th>SN</th>
<th>Putamen</th>
<th>Tectum</th>
<th>Pituitary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Mild-Mod Abnormality</td>
<td>2</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Marked Abnormality</td>
<td>7</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Total Positive</td>
<td>9</td>
<td>10</td>
<td>6</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Percent (%)</td>
<td>82</td>
<td>91</td>
<td>55</td>
<td>27</td>
<td>18</td>
</tr>
</tbody>
</table>

serves as a cofactor for numerous enzymes.16 Mn is ubiquitous in nature and widely distributed throughout the Earth’s crust, water, and atmosphere. It is also normally ingested in food and water with an average daily intake of 2.6 to 3.0 mg.17 Only 1-3.5% of ingested Mn is systemically absorbed as it is rapidly cleared by the liver and excreted into bile.18-20 Indeed, bile duct obstruction in both patients and animal models has been demonstrated to cause a marked impairment of Mn elimination.21,22 Mn intoxication has been reported to occur primarily as a consequence of industrial exposure.23 However, as Mn elimination occurs predominantly through the liver, we hypothesize that hepatic dysfunction could also lead to Mn overload. Our finding of increased blood Mn concentrations in patients with hepatic cirrhosis supports this concept.

Mn is a paramagnetic ion which shortens T1 on MRI in a concentration-dependent fashion. Parenteral administration of Mn to monkeys results in Mn accumulation and abnormal high signal intensity on T1-weighted MRI in the GP, SN, putamen, and anterior pituitary.9,24 A similar MRI pattern has been described in patients who were thought to have Mn intoxication due to: 1) long-term total parenteral nutrition containing Mn,24 2) repair and recycling of railroad track containing a Mn steel alloy,26 and 3) chronic employment in a Mn smelting plant (personal observation CWO). MRI findings have been reported to resolve following removal from the source of Mn exposure in both patients and animal models.9,20,27

The MRI abnormalities identified in patients with chronic liver disease are strikingly similar to those seen in association with Mn intoxication. In our cirrhotic patients, we noted abnormal T1 signal hyperintensity in the GP (82%), SN (91%), putamen (55%), tectum (27%), and anterior pituitary (18%). Brunberg et al.1 reported abnormal increased signal on T1-weighted images in the GP (71%), mesencephalon (40%), putamen (50%), tectum (10%), and anterior pituitary (80%) of 42 patients with chronic hepatic failure. Similarly, Kulisevsky et al.3 reported pallidal signal hyperintensity in 73% of cirrhotic patients and Inoue et al.2 noted pallidal signal hyperintensity in 56% of patients with portal-systemic encephalopathy. Interestingly, T1-weighted signal abnormalities have been reported to resolve following treatment of hepatic encephalopathy.28 Thus the pattern and time course of resolution of signal abnormalities seen in patients with chronic liver disease is virtually identical to that observed in Mn intoxication.

Mn accumulation in the brain may have important clinical consequences for patients with chronic liver disease. Mn intoxication can lead to both encephalopathy and parkinsonism.29-33 In turn, encephalopathy and parkinsonism are both well recognized features of liver disease.34-36 It is therefore reasonable to consider that Mn accumulation may account for encephalopathy and parkinsonism in patients with chronic liver disease. It is noteworthy that
Alzheimer type II astrocytes, which are characteristic findings in the GP and SN of patients with chronic liver disease, are also seen in these regions in Mn-intoxicated monkeys. Further support for this concept derives from the case an 8-year-old girl with developmental paucity of intrahepatic bile ducts who developed dystonia, tremor, and T1-weighted signal abnormalities on MRI in association with an increase in blood Mn levels. Normalization of blood Mn levels following orthotopic liver transplantation was associated with resolution of neurological abnormalities and MRI changes. Additional studies are required to assess the relationship between Mn metabolism, MRI abnormalities, and clinical dysfunction in patients with liver disease. Ultimately, direct measurement of brain Mn concentration may be required to prove that Mn accumulates in the brain of patients with liver disease. Nonetheless, in the absence of a history of Mn exposure, signal hyperintensity in the GP and SN on T1-weighted MRI should suggest the possibility of Mn accumulation due to chronic liver disease. If Mn does contribute to the development of neurologic signs and symptoms in cirrhotic patients, therapies that diminish Mn intake or enhance its elimination may prevent or reverse neurologic dysfunction.

Addendum: A paper on this topic has been recently published: (Kreiger D, Kreiger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346: 270-274.)

**REFERENCES**